Skip to main content
PMC home page
Journal of the National Medical Association logoLink to Journal of the National Medical Association
. 2000 Jul;92(7):319–326.

Efficacy and safety of cerivastatin and pravastatin in the treatment of primary hypercholesterolemia.

E Saunders 1, K Ferdinand 1, L G Yellen 1, M J Tonkon 1, S Krug-Gourley 1, M Poland 1
PMCID: PMC2608580  PMID: 10946527

Abstract

In this randomized, double-blind, parallel group study, the efficacy and safety of cerivastatin (0.3 mg) and pravastatin (20 mg) were compared in 402 patients with primary hypercholesterolemia with and without documented coronary heart disease or peripheral vascular disease. After 8 weeks of treatment, cerivastatin provided significantly greater reductions than pravastatin in low-density lipoprotein (LDL)-cholesterol (31.1% vs. 26.0%; p < 0.0001) and total cholesterol (21.1% vs. 17.8%; p < 0.0001). A greater proportion of patients treated with cerivastatin than pravastatin achieved > 30% and > 40% reductions from baseline in LDL-cholesterol. Both agents also increased high density lipoprotein-cholesterol and reduced triglycerides. Overall, 65.1% of patients treated with cerivastatin and 63.3% of patients with pravastatin achieved LDL-cholesterol goals defined by the National Cholesterol Education Program. Both drugs were well tolerated, with most adverse events being mild. These results demonstrate that cerivastatin (0.3 mg) is a highly effective 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, which enables a large proportion of patients to achieve clinically meaningful reductions in LDL-cholesterol.

Full text

PDF
319

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bischoff H., Angerbauer R., Bender J., Bischoff E., Faggiotto A., Petzinna D., Pfitzner J., Porter M. C., Schmidt D., Thomas G. Cerivastatin: pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor. Atherosclerosis. 1997 Nov;135(1):119–130. doi: 10.1016/s0021-9150(97)00188-3. [DOI] [PubMed] [Google Scholar]
  2. Blankenhorn D. H., Azen S. P., Kramsch D. M., Mack W. J., Cashin-Hemphill L., Hodis H. N., DeBoer L. W., Mahrer P. R., Masteller M. J., Vailas L. I. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med. 1993 Nov 15;119(10):969–976. doi: 10.7326/0003-4819-119-10-199311150-00002. [DOI] [PubMed] [Google Scholar]
  3. Castelli W. P., Anderson K., Wilson P. W., Levy D. Lipids and risk of coronary heart disease. The Framingham Study. Ann Epidemiol. 1992 Jan-Mar;2(1-2):23–28. doi: 10.1016/1047-2797(92)90033-m. [DOI] [PubMed] [Google Scholar]
  4. Davignon J., Hanefeld M., Nakaya N., Hunninghake D. B., Insull W., Jr, Ose L. Clinical efficacy and safety of cerivastatin: summary of pivotal phase IIb/III studies. Am J Cardiol. 1998 Aug 27;82(4B):32J–39J. doi: 10.1016/s0002-9149(98)00435-4. [DOI] [PubMed] [Google Scholar]
  5. Feillet C., Farnier M., Monnier L. H., Percheron C., Colette C., Descomps B., Crastes De Paulet A. Comparative effects of simvastatin and pravastatin on cholesterol synthesis in patients with primary hypercholesterolemia. Atherosclerosis. 1995 Dec;118(2):251–258. doi: 10.1016/0021-9150(95)05611-4. [DOI] [PubMed] [Google Scholar]
  6. Frick M. H., Elo O., Haapa K., Heinonen O. P., Heinsalmi P., Helo P., Huttunen J. K., Kaitaniemi P., Koskinen P., Manninen V. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987 Nov 12;317(20):1237–1245. doi: 10.1056/NEJM198711123172001. [DOI] [PubMed] [Google Scholar]
  7. Jacobson T. A., Chin M. M., Curry C. L., Miller V., Papademetriou V., Schlant R. C., LaRosa J. C. Efficacy and safety of pravastatin in African Americans with primary hypercholesterolemia. Arch Intern Med. 1995 Sep 25;155(17):1900–1906. [PubMed] [Google Scholar]
  8. Jones P. H., Farmer J. A., Cressman M. D., McKenney J. M., Wright J. T., Proctor J. D., Berkson D. M., Farnham D. J., Wolfson P. M., Colfer H. T. Once-daily pravastatin in patients with primary hypercholesterolemia: a dose-response study. Clin Cardiol. 1991 Feb;14(2):146–151. doi: 10.1002/clc.4960140211. [DOI] [PubMed] [Google Scholar]
  9. Jukema J. W., Bruschke A. V., van Boven A. J., Reiber J. H., Bal E. T., Zwinderman A. H., Jansen H., Boerma G. J., van Rappard F. M., Lie K. I. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation. 1995 May 15;91(10):2528–2540. doi: 10.1161/01.cir.91.10.2528. [DOI] [PubMed] [Google Scholar]
  10. Neaton J. D., Blackburn H., Jacobs D., Kuller L., Lee D. J., Sherwin R., Shih J., Stamler J., Wentworth D. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med. 1992 Jul;152(7):1490–1500. [PubMed] [Google Scholar]
  11. Sacks F. M., Pfeffer M. A., Moye L. A., Rouleau J. L., Rutherford J. D., Cole T. G., Brown L., Warnica J. W., Arnold J. M., Wun C. C. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996 Oct 3;335(14):1001–1009. doi: 10.1056/NEJM199610033351401. [DOI] [PubMed] [Google Scholar]
  12. Sasaki J., Arakawa K., Yamamoto K., Kobori S., Ageta M., Kono S. A long-term comparative trial of cerivastatin sodium, a new HMG-CoA reductase inhibitor, in patients with primary hypercholesterolemia. Clin Ther. 1998 May-Jun;20(3):539–548. doi: 10.1016/s0149-2918(98)80063-5. [DOI] [PubMed] [Google Scholar]
  13. Shepherd J., Cobbe S. M., Ford I., Isles C. G., Lorimer A. R., MacFarlane P. W., McKillop J. H., Packard C. J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995 Nov 16;333(20):1301–1307. doi: 10.1056/NEJM199511163332001. [DOI] [PubMed] [Google Scholar]
  14. Stein E. Cerivastatin in primary hyperlipidemia--a multicenter analysis of efficacy and safety. Atherosclerosis. 1998 Sep;139 (Suppl 1):S15–S22. doi: 10.1016/s0021-9150(98)00189-0. [DOI] [PubMed] [Google Scholar]
  15. Yee H. S., Fong N. T. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias. Ann Pharmacother. 1998 Oct;32(10):1030–1043. doi: 10.1345/aph.17231. [DOI] [PubMed] [Google Scholar]

Articles from Journal of the National Medical Association are provided here courtesy of National Medical Association

RESOURCES